Navigation Links
Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
Date:6/26/2012

BILLERICA, Mass., June 26, 2012 /PRNewswire/ -- Seahorse Bioscience, the world leader in manufacturing instrumentation and assay kits for measuring cellular metabolism, has announced the launch of its newest product, the XF Palmitate-BSA FAO Reagent, eliminating the need for radioactivity in fatty acid oxidation (FAO) assays.

The XF Palmitate-BSA FAO Reagent is a pre-conjugated, quality controlled fatty acid substrate in an aqueous solution that is readily absorbed and utilized by cells. Traditionally, FAO assays have been dependent on the Palmitate solubilizing, which is difficult to achieve and produces variable data.  

"For researchers probing substrate utilization and fatty acid oxidation pathways, the process is no longer dependent on one's ability to prepare Palmitate. Each lot of the Seahorse XF Palmitate-BSA Reagent is functionally tested for activity in a fatty acid oxidation assay on the XF Analyzer, ensuring consistent performance; and the pre-conjugated, non-radioactive, ready-to-use solution eliminates any requirement of a lengthy conjugation protocol, so the assay is no longer intimidating to the researcher", stated Steve Chomicz, Seahorse Vice President of Sales, Marketing & Support.

For use with both the XF96 and XF24 Extracellular Flux Analyzers, the new XF Palmitate-BSA FAO Reagent introduces a standardized, ready-to-use, quality-controlled solution for measuring fatty acid oxidation providing true functional information, and consistent results in every assay, without radioactivity.

The XF Palmitate-BSA FAO Reagent will further advance the study of cellular bioenergetics, helping scientists to better understand the connection of physiological traits of cells with genomic and proteomic data. This knowledge will generate new insights into cellular bioenergetics and mitochondrial dysfunction, leading to a greater understanding, and new treatments of diseases as the human lifespan increases.

Abou
'/>"/>

SOURCE Seahorse Bioscience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. HemaClear Launches Activity in APAC
2. Elsevier Launches New Journal: Learning, Culture and Social Interaction
3. Bode Technology Launches Same-Day DNA Service For Faster Response to Law Enforcement and Justice System
4. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
5. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
6. Pittcon 2013 Launches New Website
7. Comprehensive Resource for Food Safety Diagnostics – Romer Labs Launches New Website
8. Ekahau Launches Next Generation Wi-Fi RTLS Staff Badge and Pager
9. AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services
10. Neogen launches the fastest molecular pathogen test
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... 21, 2013 Smarter Security, Inc., provider ... today announced that Genzyme, a Sanofi company and leading ... Detective® CL for a multi-use facility in the United ... other Genzyme buildings, this latest order underscores the satisfaction ... tailgate detection device improving doorway access control. ...
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... review, the Company is initiating a U.S.,Phase ... REOLYSIN(R) in,combination with paclitaxel and carboplatin in ... K-RAS or EGFR-activated tumours. The Principal,Investigator is ...
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (NASDAQ: OGXI ... that it has granted to Eagle Pharmaceuticals, ... commercialize TOCOSOL(R),Paclitaxel. Under the terms of the ... from future TOCOSOL Paclitaxel sales and a,percentage ...
... Germany, Sept. 1 ,Boston Scientific Corporation (NYSE: ... its landmark SYNTAX trial comparing percutaneous coronary ... Stent,System to contemporary coronary artery bypass graft ... significant differences,between PCI and CABG in rates ...
Cached Biology Technology:/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5
(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... "Basic science and clinical medicine move at different pace ... strategies to manage cancer patients. We need to efficiently translate ... in the clinic." Sherene Loi and Fabrice Andr, ... four major areas: , Molecular pathology, the roots ...
... award-winning research project, funded by the British Heart Foundation (BHF), ... how doctors predict a patient,s risk of having a heart ... a BHF Centre of Research Excellence, in collaboration with the ... of combining PET and CT scanning to image the disease ...
... Mass. A team of kinesiology researchers led by ... recently received a 2.5-year, $975,000 grant through the Navy ... study how the average 100-lb. equipment load carried by ... affects their survivability, likelihood of injury and ability to ...
Cached Biology News:Fourth IMPAKT Breast Cancer Conference 2Fourth IMPAKT Breast Cancer Conference 3Scientists develop new technique that could improve heart attack prediction 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
... Mynox is the first biological ... killing them, and not just ... the only anti-mycoplasma agent that ... virus stocks directly. The cytotoxicity ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: